|
US5837258A
(en)
|
1991-08-30 |
1998-11-17 |
University Of South Florida |
Induction of tissue, bone or cartilage formation using connective tissue growth factor
|
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
|
US20040259247A1
(en)
|
2000-12-01 |
2004-12-23 |
Thomas Tuschl |
Rna interference mediating small rna molecules
|
|
US20050282188A1
(en)
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
|
US20080188430A1
(en)
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
|
CN1608133A
(zh)
|
2001-10-26 |
2005-04-20 |
里伯药品公司 |
双链核糖核酸用于治疗正(+)链rna病毒感染的用途
|
|
US20040138163A1
(en)
|
2002-05-29 |
2004-07-15 |
Mcswiggen James |
RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
AU2003260370B2
(en)
|
2002-08-05 |
2008-05-22 |
Silence Therapeutics Gmbh |
Further novel forms of interfering RNA molecules
|
|
EP2305812A3
(en)
|
2002-11-14 |
2012-06-06 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
WO2004080406A2
(en)
|
2003-03-07 |
2004-09-23 |
Alnylam Pharmaceuticals |
Therapeutic compositions
|
|
US20040198640A1
(en)
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
|
US20050136437A1
(en)
|
2003-08-25 |
2005-06-23 |
Nastech Pharmaceutical Company Inc. |
Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
|
|
WO2005062937A2
(en)
|
2003-12-22 |
2005-07-14 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
|
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
|
WO2005079533A2
(en)
|
2004-02-17 |
2005-09-01 |
University Of Massachusetts |
Methods and compositions for mediating gene silencing
|
|
AU2005222902B2
(en)
|
2004-03-12 |
2010-06-10 |
Alnylam Pharmaceuticals, Inc. |
iRNA agents targeting VEGF
|
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
JP2008512500A
(ja)
|
2004-09-10 |
2008-04-24 |
ソマジェニックス インコーポレーティッド |
ウィルス遺伝子発現を効率的に阻害する低分子干渉ｒｎａおよびその使用方法
|
|
US7528118B2
(en)
|
2004-09-24 |
2009-05-05 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of ApoB and uses thereof
|
|
TWI386225B
(zh)
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
|
|
US20060142228A1
(en)
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
|
CA2603842A1
(en)
|
2005-04-08 |
2006-10-19 |
Nastech Pharmaceutical Company Inc. |
Rnai therapeutic for respiratory virus infection
|
|
US8067572B2
(en)
|
2005-05-25 |
2011-11-29 |
The University Of York |
Hybrid interfering RNA
|
|
EP1896069B1
(en)
|
2005-06-24 |
2013-03-13 |
Intervet International BV |
Inactivated chimeric vaccines and related methods of use
|
|
FR2890859B1
(fr)
|
2005-09-21 |
2012-12-21 |
Oreal |
Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
|
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
|
WO2007089607A2
(en)
|
2006-01-26 |
2007-08-09 |
University Of Massachusetts |
Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
|
|
CA2913655A1
(en)
|
2006-01-27 |
2007-08-09 |
Biogen Ma Inc. |
Nogo receptor antagonists
|
|
US20070218495A1
(en)
|
2006-03-16 |
2007-09-20 |
Dharmacon, Inc. |
Methods, libraries and computer program products for gene silencing with reduced off-target effects
|
|
US7700541B2
(en)
|
2006-04-06 |
2010-04-20 |
Nitto Denko Corporation |
Biodegradable cationic polymers
|
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
|
CA2679867A1
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof
|
|
WO2008109372A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting pdgf gene expression and uses thereof
|
|
US20100105134A1
(en)
*
|
2007-03-02 |
2010-04-29 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting gene expression and uses thereof
|
|
US8258286B2
(en)
|
2007-04-26 |
2012-09-04 |
University Of Iowa Research Foundation |
Reduction of off-target RNA interference toxicity
|
|
US20090004668A1
(en)
|
2007-06-22 |
2009-01-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Pre-miRNA loop-modulated target regulation
|
|
CA2692632A1
(en)
*
|
2007-07-06 |
2009-01-15 |
Intradigm Corporation |
Methods and compositions for treatment of cancer and other angiogenesis-related diseases
|
|
WO2009020344A2
(en)
|
2007-08-06 |
2009-02-12 |
Postech Acad Ind Found |
Small interfering rnas (sirnas) controlling multiple target genes and method for preparing the same
|
|
JP2010537640A
(ja)
|
2007-08-27 |
2010-12-09 |
ボストン バイオメディカル， インコーポレイテッド |
マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物
|
|
DK2548962T3
(en)
|
2007-09-19 |
2016-04-11 |
Applied Biosystems Llc |
Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof
|
|
AU2008306455C1
(en)
|
2007-10-03 |
2014-04-17 |
Quark Pharmaceuticals, Inc. |
Novel siRNA structures
|
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
|
KR100949791B1
(ko)
|
2007-12-18 |
2010-03-30 |
이동기 |
오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
|
|
JP2011518116A
(ja)
|
2008-02-21 |
2011-06-23 |
ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション |
トール様受容体３拮抗薬としての超小型ｒｎａ
|
|
EP2318528A1
(en)
|
2008-07-24 |
2011-05-11 |
Rxi Pharmaceuticals Corporation |
Rnai constructs and uses therof
|
|
WO2010026660A1
(ja)
|
2008-09-08 |
2010-03-11 |
学校法人福岡大学 |
Ｚｆａｔ遺伝子発現抑制ｒｎａ
|
|
CA2746527A1
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
|
US20100227920A1
(en)
|
2008-09-29 |
2010-09-09 |
The Regents Of The University Of California |
Aldehyde dehydrogenase inhibitors as novel depigmenting agents
|
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
WO2010094491A1
(en)
*
|
2009-02-18 |
2010-08-26 |
Silence Therapeutics Ag |
Means for inhibiting the expression of ang2
|
|
WO2010107952A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
CN104651362A
(zh)
|
2009-04-03 |
2015-05-27 |
戴瑟纳制药公司 |
利用不对称双链rna特异性抑制kras的方法和组合物
|
|
US8472766B2
(en)
|
2009-08-14 |
2013-06-25 |
Massachusetts Institute Of Technology |
Waveguide coupler having continuous three-dimensional tapering
|
|
KR101207561B1
(ko)
|
2009-12-15 |
2012-12-04 |
주식회사 코리아나화장품 |
티로시나제의 발현을 저해하는 ｓｉＲＮＡ 올리고뉴클레오타이드 및 이를 함유하는 화장료 조성물
|
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
|
CN106074591B
(zh)
|
2010-03-24 |
2020-01-14 |
菲奥医药公司 |
眼部症候中的rna干扰
|
|
US20130115613A1
(en)
|
2010-05-12 |
2013-05-09 |
Val-Chum, Limited Partnership |
Screening assays based on mag and/or abhd6 for selecting insulin secretion promoting agent
|
|
CA2812046A1
(en)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified irna agents
|
|
CN103080314B
(zh)
*
|
2010-09-30 |
2016-04-13 |
Lsip基金运营联合公司 |
显性突变基因表达抑制剂
|
|
DK2631291T3
(da)
|
2010-10-22 |
2019-06-11 |
Olix Pharmaceuticals Inc |
Nukleinsyremolekyler, der inducerer rna-interferens, og anvendelser deraf
|
|
AU2011338682B2
(en)
|
2010-12-06 |
2017-04-27 |
Quark Pharmaceuticals, Inc. |
Double stranded oligonucleotide compounds comprising threose modifications
|
|
CN102719432B
(zh)
|
2011-03-29 |
2013-10-23 |
南京大学 |
特异性抑制肿瘤凋亡抑制基因Bcl2的双链不对称小核酸干扰分子asiRNA及其应用
|
|
KR101590586B1
(ko)
|
2011-05-30 |
2016-02-01 |
성균관대학교산학협력단 |
표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 ｒｎａ
|
|
CN108148838A
(zh)
|
2012-05-22 |
2018-06-12 |
奥利克斯医药有限公司 |
具有细胞内穿透能力的诱导rna干扰的核酸分子及用途
|
|
US9611473B2
(en)
|
2012-09-12 |
2017-04-04 |
Quark Pharmaceuticals, Inc. |
Double-stranded nucleic acid compounds
|
|
WO2015002513A2
(ko)
|
2013-07-05 |
2015-01-08 |
(주)바이오니아 |
호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물
|
|
EP3027223A1
(en)
|
2013-07-31 |
2016-06-08 |
QBI Enterprises Ltd. |
Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
|
|
US9790506B2
(en)
|
2013-10-02 |
2017-10-17 |
The Regents Of The University Of California |
Diagnostic and screening methods for atopic dermatitis
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
WO2015171641A1
(en)
|
2014-05-05 |
2015-11-12 |
Brigham And Women's Hospital, Inc. |
Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
|
|
US9139648B1
(en)
*
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
EP3277811B1
(en)
|
2015-04-03 |
2020-12-23 |
University of Massachusetts |
Fully stabilized asymmetric sirna
|
|
KR102772402B1
(ko)
|
2015-07-27 |
2025-02-26 |
올릭스 주식회사 |
멜라닌 생성을 억제하는 rna 복합체
|
|
EP4454637A3
(en)
|
2015-11-16 |
2025-01-08 |
Olix Pharmaceuticals, Inc. |
Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
|
|
CA3022877A1
(en)
|
2016-02-02 |
2017-08-10 |
Olix Pharmaceuticals, Inc. |
Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb
|
|
KR102825946B1
(ko)
|
2016-02-02 |
2025-06-27 |
올릭스 주식회사 |
IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
|
|
WO2017178883A2
(en)
|
2016-04-11 |
2017-10-19 |
Olix Pharmaceuticals, Inc. |
Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
|
|
KR101916652B1
(ko)
|
2016-06-29 |
2018-11-08 |
올릭스 주식회사 |
작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
|
|
US11591600B2
(en)
|
2017-02-10 |
2023-02-28 |
OliX Pharmaceuticals. Inc. |
Long double-stranded RNA for RNA interference
|